#Precigen

@newsen.bsky.social

1 month ago

New Guidelines Endorse PAPZIMEOS as First-Line Therapy for Recurrent Respiratory Papillomatosis An expert consensus has recommended PAPZIMEOS as the new first-line treatment for adults with recurrent respiratory papillomatosis, signaling a shift from surgical options.

New Guidelines Endorse PAPZIMEOS as First-Line Therapy for Recurrent Respiratory Papillomatosis #United_States #Germantown #RRP #Precigen #PAPZIMEOS

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Precigen's PAPZIMEOS Therapy Gains Momentum and Acceptance for RRP Treatment at J.P. Morgan Healthcare Conference At the J.P. Morgan Healthcare Conference, Precigen highlights PAPZIMEOS, the first FDA-approved therapy for recurrent respiratory papillomatosis, showcasing rapid adoption and patient enrollment.

Precigen's PAPZIMEOS Therapy Gains Momentum and Acceptance for RRP Treatment at J.P. Morgan Healthcare Conference #USA #FDA_Approval #Germantown #Precigen #PAPZIMEOS

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Precigen's PAPZIMEOS Receives FDA Approval, Revolutionizing RRP Treatment Landscape Precigen, Inc. announces significant advancements with its FDA-approved PAPZIMEOS for recurrent respiratory papillomatosis (RRP), marking a milestone in the treatment options for affected adults.

Precigen's PAPZIMEOS Receives FDA Approval, Revolutionizing RRP Treatment Landscape #United_States #Germantown #RRP #Precigen #PAPZIMEOS

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Precigen Reports Promising Long-Term Effects of PAPZIMEOS for RRP Patients Precigen announces long-term outcomes showcasing substantial and sustained responses in adults with recurrent respiratory papillomatosis after PAPZIMEOS treatment.

Precigen Reports Promising Long-Term Effects of PAPZIMEOS for RRP Patients #United_States #Germantown #RRP #Precigen #PAPZIMEOS

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

EVERSANA Selected by Precigen for U.S. Launch of PAPZIMEOS Precigen has chosen EVERSANA for the U.S. commercialization of PAPZIMEOS, enhancing rare disease therapy access. Explore their partnership.

EVERSANA Selected by Precigen for U.S. Launch of PAPZIMEOS #USA #Chicago #EVERSANA #Precigen #PAPZIMEOS

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Precigen Secures Up to $125 Million for Strategic Growth in Precision Medicine Precigen, Inc. has announced a credit facility agreement that provides up to $125 million to enhance commercialization of PAPZIMEOS and support international expansion.

Precigen Secures Up to $125 Million for Strategic Growth in Precision Medicine #USA #Germantown #Precigen #PAPZIMEOS #Pharmakon_Advisors

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Precigen to Engage in Virtual Fireside Chats Discussing Innovative Treatments Precigen, Inc. will participate in virtual fireside chats discussing their FDA-approved therapy for recurrent respiratory papillomatosis, highlighting advancements in precision medicine.

Precigen to Engage in Virtual Fireside Chats Discussing Innovative Treatments #United_States #FDA_Approval #Germantown #Precigen #Virtual_Chats

0 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

7 months ago

Click Subscribe #Precigen #FDAApproval #RRP #PAPZIMEOS #Biopharmaceuticals

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Precigen’s PAPZIMEOS: A Revolutionary Therapy for Recurring Respiratory Papillomatosis Approved by the FDA Precigen's PAPZIMEOS has achieved full FDA approval as the first and only therapy for adults suffering from recurrent respiratory papillomatosis, marking a significant advancement in treatment options.

Precigen’s PAPZIMEOS: A Revolutionary Therapy for Recurring Respiratory Papillomatosis Approved by the FDA #USA #Germantown #RRP #Precigen #PAPZIMEOS

0 0 0 0

pharmaphorum

@pharmaphorum.bsky.social

7 months ago

FDA clears Precigen's rare tumour immunotherapy Precigen has won approval in the US for a first-in-class immunotherapy for recurrent respiratory papillomatosis, Papzimeos, its first product.

#Precigen has won approval in the US for a first-in-class immunotherapy for recurrent respiratory #papillomatosis (RRP), a rare, benign #tumour that can cause significant health challenges.

pharmaphorum.com/news/fda-cle...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

9 months ago